LifeMD is one of many telehealth programs competing in GLP-1 weight management
Working With Healthcare Providers For Canadian patients pursuing FDA-approved medications once Retatrutide receives approval, the process typically involves initial consultation to establish obesity diagnosis and discuss treatment options, baseline laboratory work including metabolic panel, lipid profile, and A1C if diabetic, discussion of contraindications and potential drug interactions, prescription and prior authorization if required by insurance, and scheduled follow-up appointments for monitoring
In 2,595 adults aged 5471, omnivorous participants produced more TMAO than vegans or vegetarians after L-carnitine consumption
If you are experiencing irregular periods on a GLP-1 medication, discuss this with your prescribing clinician
Patients most commonly report increased energy, improved mental clarity, and enhanced fat loss when combined with other treatments
Foundayo (Orforglipron) Released in April 2026, Foundayo is the newest oral GLP-1 medication, offering unparalleled dosing flexibility
